


# Poster & Exhibition Hall

## Kyoto International Conference Center

### Event Hall 1F



## Day 1

Friday, October 19 16 : 10 ~ 17 : 40

|    |   |    |  |
|----|---|----|--|
| 23 | Pediatrics: Immune Deficiency<br>PS-1-358~365                                       | 24 | Pediatrics: Leukemia<br>PS-1-366~372   |
| 21 | Fungus Infection 1<br>PS-1-351~357<br>Targeted Therapy: Basic Study<br>PS-1-327~335 | 22 | Bacterial Infection 2<br>PS-1-344~350<br>Bacterial Infection 1<br>PS-1-336~343 |
| 19 | SCT: Infection 2<br>PS-1-319~326<br>SCT: Engraftment<br>PS-1-292~299                | 20 | SCT: Infection 1<br>PS-1-308~318<br>SCT: GVHD<br>PS-1-300~307                  |
| 17 | SCT: Conditioning<br>PS-1-283~291<br>TPOR Agonists 1<br>PS-1-259~266                | 18 | TTP/Thrombosis<br>PS-1-276~282<br>TPOR Agonists 2<br>PS-1-267~275              |
| 15 | ITP<br>PS-1-251~258<br>MM: Pathophysiology<br>PS-1-229~235                          | 16 | MM/Related Diseases 2<br>PS-1-244~250<br>MM/Related Diseases 1<br>PS-1-236~243 |
| 13 | MM: Basic Study<br>PS-1-221~228<br>DLBCL: Case Study<br>PS-1-196~203                | 14 | DLBCL: Elderly Cases<br>PS-1-213~220<br>B-NHL: Therapy<br>PS-1-204~212         |
| 11 | DLBCL: Pathophysiology<br>PS-1-187~195<br>NHL: Bendamustine 1<br>PS-1-163~170       | 12 | NHL: Bendamustine 3<br>PS-1-179~186<br>NHL: Bendamustine 2<br>PS-1-171~178     |
| 9  | MCL, Low-grade B-NHL<br>PS-1-155~162<br>ML: Basic Study<br>PS-1-131~138             | 10 | Low-grade B-NHL<br>PS-1-147~154<br>ML: Pathophysiology<br>PS-1-139~146         |
| 7  | Ph+ALL<br>PS-1-123~130<br>CML: Clinical Study 1<br>PS-1-98~106                      | 8  | ALL<br>PS-1-115~122<br>CML: Clinical Study 2<br>PS-1-107~114                   |
| 5  | CML: Case Study<br>PS-1-89~97<br>MDS: Case Study<br>PS-1-65~72                      | 6  | MDS: Case Study<br>PS-1-81~88<br>MDS: Novel Drugs<br>PS-1-73~80                |
| 3  | MDS: Pathophysiology<br>PS-1-56~64<br>AML: Basic Study<br>PS-1-32~39                | 4  | AML: Clinical Study<br>PS-1-48~55<br>AML: Case Study<br>PS-1-40~47             |
| 1  | PNH/Bone Marrow Failure<br>PS-1-25~31<br>Hematopoiesis 1<br>PS-1-1~8                | 2  | PNH/Eculizumab<br>PS-1-16~24<br>Hematopoiesis 2<br>PS-1-9~15                   |

## Day 2

Saturday, October 20 17 : 00 ~ 18 : 30

|    |   |    |  |
|----|---|----|--|
| 23 | Viral Infection etc. 2<br>PS-2-356~360  | 24 | Pediatrics: Clinical Trial, Others<br>PS-2-367~373<br>Pediatrics: JMML, Anemia, Others<br>PS-2-361~366 |
| 21 | Viral Infection etc. 1<br>PS-2-349~355<br>Transfusion/Others<br>PS-2-325~332              | 22 | Fungus Infection 2<br>PS-2-341~348<br>Targeted Therapy: Clinical Study<br>PS-2-333~340                 |
| 19 | Immune Cell Therapy<br>PS-2-317~324<br>SCT: Myeloid Malignancy<br>PS-2-293~299            | 20 | Cell Therapy: Basic Study<br>PS-2-307~316<br>SCT: Others<br>PS-2-300~306                               |
| 17 | SCT: Lymphoid Malignancy<br>PS-2-285~292<br>Acquired Coagulation Disorder<br>PS-2-259~266 | 18 | Thrombosis/Hemostasis<br>PS-2-275~284<br>rTM/DIC<br>PS-2-267~274                                       |
| 15 | Hemophilia<br>PS-2-251~258<br>MM: Thalidomide<br>PS-2-231~234                             | 16 | MM: SCT<br>PS-2-243~250<br>MM: Lenalidomide<br>PS-2-235~242  |
| 13 | MM: Velcade<br>PS-2-222~230<br>Double Hit Lymphoma<br>PS-2-198~205                        | 14 | ML: PET-CT/Imaging<br>PS-2-214~221<br>ML: Complications<br>PS-2-206~213                                |
| 11 | ML: Rare Cases<br>PS-2-190~197<br>ATL: Pathophysiology<br>PS-2-166~173                    | 12 | HIV-related Lymphoma<br>PS-2-182~189<br>ML: Case Study<br>PS-2-174~181                                 |
| 9  | PTCL: Pathophysiology<br>PS-2-158~165<br>Hodgkin Lymphoma/T-NHL<br>PS-2-134~141           | 10 | NK/T Lymphoma<br>PS-2-150~157<br>T-NHL: Case Study<br>PS-2-142~149                                     |
| 7  | CNS Lymphoma<br>PS-2-125~133<br>MPN: Clinical Study<br>PS-2-99~107                        | 8  | IVLBCL<br>PS-2-116~124<br>EBV/B-NHL, Immunodeficiency<br>PS-2-108~115                                  |
| 5  | CML/MPN<br>PS-2-90~98<br>MDS: Azacitidine 2<br>PS-2-66~73                                 | 6  | MPN: Basic Study<br>PS-2-82~89<br>MDS: Azacitidine 3<br>PS-2-74~81                                     |
| 3  | MDS: Azacitidine 1<br>PS-2-58~65<br>AML: Case Study<br>PS-2-35~42                         | 4  | APL<br>PS-2-51~57<br>AML: Clinical Study<br>PS-2-43~50   |
| 1  | Hemolytic Anemia<br>PS-2-27~34<br>Hematopoiesis 3<br>PS-2-1~8                             | 2  | Aplastic Anemia<br>PS-2-18~26<br>Iron Metabolism<br>PS-2-9~17  |